Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233869 · ClinicalTrials.gov registry record · Phase 2
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT01233869 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 172 participants.
The verdict
NCT01233869, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kidney volume greater than or equal to 750 cc and eGFR greater than or equal to 60 mL/min/1.73m2.
Interventions
- DRUG Placebo
- DRUG Bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01233869
The ClinicalTrials.gov registry entry for NCT01233869 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01233869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01233869 about?
NCT01233869 is a clinical study titled "Bosutinib For Autosomal Dominant Polycystic Kidney Disease". This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kidney volume greater than or equal to 750 cc and eGFR greater than or equal to 60 mL/min/1.73m2.
What is the current status of trial NCT01233869?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2010-12. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01233869?
The interventions under investigation include: Placebo (DRUG), Bosutinib (DRUG).
Who is sponsoring clinical trial NCT01233869?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.